PAIN TRIGGERS
Medication gradually stops working or efficiency decreases significantly over time.
Doctors iteratively increase the dosage but it fails to resolve the long-term effectiveness drop.
SaaS· ADHD patientsPain 8.00/10WTP 6.0/10Market 7.0/10Validation 8.0Confidence 90%Jun 28, 2026
FocusCycle: Patient-Led Stimulant Efficacy & Tolerance Tracker
Stimulant medications lose efficacy over time, leading to dosage escalation spirals, executive dysfunction return, and an inability to track the impact of lifestyle factors (protein, breaks, cycle) on medication performance.
adhddata-managementhealthcaremental-healthmobile-appproductivitysaastracking
1
STAGE 01 · PROBLEM
Is the problem real?
CANONICAL PROBLEM
ADHD patients experience their prescribed stimulant medications (like Vyvanse) losing effectiveness or tapering off over time, leading to a return of severe executive dysfunction and emotional distress.
FREQUENCY
Multiple repeated complaints in the post and comments.
INTENSITY
Users explicitly describe existing tools as bloated/overkill and mention workaround behavior.
EVIDENCE
Struggling after Vyvanse lost its effect. Looking for advice
ADHD1513
Struggling after Vyvanse lost its effect. Looking for advice
ADHD1513
Struggling after Vyvanse lost its effect. Looking for advice
ADHD1513
2
STAGE 02 · CUSTOMER
Who feels this pain?
TARGET USERS
ADHD patientsMedicated A D H D Patients Experiencing Tolerance
Adults managing ADHD with stimulants who struggle with long-term baseline management and medication tapering effects.
Context
Find a sustainable medical or behavioral strategy to manage ADHD symptoms consistently when their primary medication loses its initial efficacy.
Taking selective 'tolerance breaks' on weekends or specific days of the week to restore medication efficacy.
Splitting the daily medication into staggered, multiple doses throughout the day.
Current Workarounds
Taking manual weekend tolerance breaks unguided
Manually tracking high-protein meals and water intake in Notes apps
Splitting daily capsules arbitrarily or staggering doses
3
STAGE 03 · MARKET
Where's the gap?
EXISTING SOLUTION GAPS
Standard clinical treatment pathways rely heavily on escalating stimulant doses, which can fail to address tolerance or underlying physiological factors.
Patients lack education from psychiatrists regarding the temporary nature of the initial medication 'high/euphoria' vs. long-term baseline management.
Generic formulations or interactions with other medications (like GLP-1 agonists) can disrupt drug delivery and efficacy.
OPPORTUNITY & VALUE
Why Now
Repeated complaints focus heavily on medications gradually stopping working over time and doctors chasing the honeymoon phase with continuous dosage increases without fixing the root long-term management issue.
Value Proposition
Unlike generic habit or mood trackers, this is specifically optimized around the neuro-pharmacology of ADHD stimulants, focusing exclusively on active/inactive windows, tolerance metrics, and physical catalysts like protein intake.
Product Direction
A mobile logging and analytics app specifically built for ADHD medication management that correlates daily stimulant efficacy with tolerance breaks, protein intake, hydration, sleep, and GLP-1/other drug interactions to help users find their optimal baseline without relying solely on dosage increases.
4
STAGE 04 · BUSINESS
How does it make money?
MONETIZATION
$4.99/moBilled monthly, with a 7-day free trial
Model
SaaS subscription
WILLINGNESS TO PAY
Users are experiencing severe executive dysfunction and emotional distress when their medication fails. They are spending money on doctors who just iteratively increase dosages, making a $5 tool that provides actionable medical insights highly attractive.
5
STAGE 05 · EXECUTION
How do you ship it?
MVP PLAN
“Track your ADHD medication baseline and defeat tolerance cycles.”
A mobile logging and analytics app specifically built for ADHD medication management that correlates daily stimulant efficacy with tolerance breaks, protein intake, hydration, sleep, and GLP-1/other drug interactions to help users find their optimal baseline without relying solely on dosage increases.
Core Features
Quick daily 3-second efficacy and task-initiation logging
Structured logging for tracking tolerance breaks and staggered doses
Dietary correlation logging (protein intake timers and hydration tracking)
Exportable PDF summary reports for psychiatry appointments
Weekly Roadmap
1
W1-W2
Core micro-logging mechanism for medication timing and baseline efficacy works.
- •Build mobile-responsive UI for ultra-fast daily tracking
- •Implement basic timers tracking medication 'on-set' vs 'crash' times
- •Set up local database for tracking user inputs securely
2
W3-W4
Catalyst logs (protein, hydration, tolerance breaks) and correlation charts added.
- •Add simple toggles for high-protein meals, tolerance days, and water intake
- •Build basic correlation visualizer graphing efficacy against lifestyle metrics
- •Implement automated behavioral reminders at typical crash hours
3
W5
Export feature functional and private beta with 20 ADHD users completed.
- •Develop a clean 'Export PDF for Doctor' feature
- •Launch TestFlight/Beta build to selected community testers from r/ADHD
- •Fix friction points in onboarding to prevent cognitive overload
4
W6
Public launch with Stripe integration and active community push.
- •Integrate Stripe billing model for basic subscription access
- •Launch product publicly on Product Hunt and subreddits with an informational guide
- •Gather first cohort of analytics on conversion and repeat logging habits
Launch Strategy
Launch in active ADHD communities such as r/ADHD, r/Vyvanse, and partner with neurodivergent creators on X and TikTok who talk about executive dysfunction and medication management.
RISKS & ASSUMPTIONS
Top Risks
User retention due to executive dysfunction
ADHD patients inherently struggle with routine tasks; if the logging mechanism isn't ultra-low friction, users will abandon it within weeks.
Medical liability boundary issues
Providing tracking algorithms that relate to prescription drug efficacy could cross into giving unauthorized medical advice if messaging is unchecked.
Platform dependency for notifications
Relies heavily on perfectly timed mobile notifications to catch users during active and crash windows to gather valid data.
6
STAGE 06 · DECISION
Should you build it?
NEED A CLEARER CALL?
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoWhat this score means
This opportunity scores well above the median for ideas surfaced by MonetScope, with a validation sub-score of 8/10 against 3 independently sourced evidence signals. A "strong" rating in this band typically means the pain signal is consistent and recurring across multiple discussions, but one of the three pillars (severity, willingness to pay, or competitor weakness) is somewhat softer than top-tier opportunities. Founders evaluating this should focus customer discovery on the softest pillar first — confirming the gap before committing engineering time to a build.
Why this matters for SaaS founders
It sits at the intersection of "adhd", "data-management", "healthcare", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. SaaS opportunities at this stage tend to win on the strength of their initial wedge — a single workflow that the target user runs every week, where the existing solution is either spreadsheets, a clunky incumbent feature, or a manual process they hate. The build cost is moderate; the distribution cost is everything. The MonetScope pipeline surfaces this category alongside other saas signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
Frequently asked questions
Is "FocusCycle: Patient-Led Stimulant Efficacy & Tolerance Tracker" a real validated startup idea or just an AI-generated suggestion?
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
How recent is the underlying data for adhd?
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most saas opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
What's the difference between "overall score" and "validation score"?
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.